https://www.selleckchem.com/products/agi-6780.html The Multiple Comparison Procedure - Modelling (MCP-Mod) method was qaulified by regulatory agencies (e.g., EMA in 2014 and FDA in 2016) as an efficient statistical method for Phase 2 dose-finding studies when there is uncertainty about dose-response relationship. As this is a relatively new approach, there is limited literature providing practical guidance on its application. In this paper, we evaluated the performance of the MCP-Mod method for clinical trials with a binary primary endpoint, focusing on (1) the impact of sample size, data variability and treatment effect size on the performance of the MCP-Mod, (2) the impact of candidate model mis-specification, and (3) optimal sample allocation under a fixed sample size. The evaluation was performed via simulations under different scenarios.Patients with coronary artery disease remain at increased risk of recurrent life-threatening cardiovascular events even after adequate guideline-based treatment of conventional risk factors, including blood lipid levels. Inflammation is a critical pathway in the pathogenesis of atherosclerosis and is independently associated with risk of recurrent cardiovascular events. Leukotrienes are potent pro-inflammatory and vasoactive mediators synthesized by leukocytes in atherosclerotic lesions. AZD5718 is a novel antagonist of 5-lipoxygenase activating protein that suppresses leukotriene biosynthesis. FLAVOUR is a phase IIa efficacy and safety study of AZD5718 in patients with myocardial infarction 1-4 weeks before randomization. Stenosis of the left anterior descending coronary artery after percutaneous intervention must be less then 50%, and Thrombolysis In Myocardial Infarction flow grade must be ≥ 2. Enrolled participants receive standard care plus oral AZD5718 200 mg, 50 mg, or placebo once daily for up to 12 potential benefits of AZD5718 treatment in patients with coronary artery disease. The asthma prevalence of Taiwanese adoles